Plasma sRAGE and N‐(carboxymethyl) lysine in patients with CHF and/or COPD. (17th April 2013)

• Record Type: Journal Article
• Authors: Boschetto, Piera; Campo, Ilaria; Stendardo, Mariarita; Casimirri, Enrico; Tinelli, Carmine; Gorrini, Marina; Ceconi, Claudio; Fucili, Alessandro; Potena, Alfredo; Papi, Alberto; Ballerin, Licia; Fabbri, Leonardo; Luisetti, Maurizio
• Is Part Of: European journal of clinical investigation. Volume 43:Number 6(2013:Jun.)
• Page Start: 562
• Page End: 569
• Publication Date: 2013-04-17
• Subjects: Pathology -- Periodicals; Medical research -- Periodicals; 616.075
• DOI: 10.1111/eci.12079
• Languages: English
• ISSNs: 0014-2972

Abstract

<abstract abstract-type="main" xml:lang="en" id="eci12079-abs-0001"> <title>Abstract</title> <sec id="eci12079-sec-0001" sec-type="section"> <title>Background</title> <p>Knowledge of the role of the receptor for advanced glycation end products (RAGE), particularly its soluble form (sRAGE), and of its advanced glycation end product (AGE) ligand, N‐(carboxymethyl)lysine adducts (CML), is limited in chronic heart failure (CHF) and in chronic obstructive pulmonary disease (COPD). We evaluated whether the AGE/RAGE system is activated in stable CHF and COPD, and whether plasma sRAGE and CML levels are affected by clinical and functional parameters.</p> </sec> <sec id="eci12079-sec-0002" sec-type="section"> <title>Materials and methods</title> <p>We measured plasma levels of sRAGE and CML using a sandwich enzyme‐linked immunosorbent assay (ELISA) in 143 subjects, aged ≥ 65 years, divided into five groups: 58 with CHF, 23 with COPD, 27 with CHF+COPD and 35 controls (17 healthy smokers and 18 healthy nonsmokers). Individuals with diabetes were excluded from the study.</p> </sec> <sec id="eci12079-sec-0003" sec-type="section"> <title>Results</title> <p>Plasma levels of sRAGE and CML were higher in CHF patients than in controls [sRAGE: 0·48 (0·37–0·83) vs. 0·42 (0·29–0·52) ng/mL, <italic>P</italic> = 0·01; CML: 1·95 (1·58–2·38) vs. 1·68 (1·43–2·00) ng/mL, <italic>P</italic> = 0·01]. By contrast, sRAGE and CML were not different between both COPD and CHF+COPD patients and controls (<italic>P</italic> > 0·05). N‐terminal pro‐brain natriuretic peptide (Nt‐pro BNP) correlated with sRAGE, but not with CML, in the patient groups: CHF (<italic>r</italic> = 0·43, <italic>P</italic> < 0·001), COPD (<italic>r</italic> = 0·77, <italic>P</italic> < 0·0001) and CHF/COPD (<italic>r</italic> = 0·43, <italic>P</italic> = 0·003).</p> </sec> <sec id="eci12079-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Plasma levels of sRAGE and CML are increased in CHF, but not in COPD patients. The robust association between NT‐pro BNP, a diagnostic and prognostic marker in CHF, and sRAGE concentrations might suggest a possible BNP pathway of amplification of inflammation <italic>via</italic> the AGE/RAGE system.</p> </sec> </abstract>